Pharmaceutical

Image

Global Influenza Drug Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Influenza Drug Market, By Type (Influenza A viruses, Influenza B viruses, Influenza C virus, Influenza D viruses), Mechanism of Action Type (Cap-Dependent Endonuclease Inhibitor, Neuraminidase Inhibitor, Matrix-2 (M2) Protein Inhibitor, Viral Uncoating Inhibitors, Immunomodulators, Non steroidal Anti-Inflammatory Drug, Alpha-adrenergic Receptors Agonist and N-Methyl-D-aspartate Receptor Inhibitor), Vaccine Type (Quadrivalent, Trivalent, Anflu and Other), Treatment Type (Medication, Chemoprophylaxis and Others), Route of Administration (Oral, Intradermal, Intramuscular, Intranasal, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.

Influenza Drug Market

Influenza Drug Market Analysis and Size

The rising prevalence of influenza will drive the demand for influenza drugs globally. The rising geriatric population, which is the most susceptible to this illness, is another factor inducing growth in the demand for influenza drugs. Increased focus on research and development activities to come up with novel drugs and therapies will, in turn, create lucrative growth opportunities for the influenza drug market.       

Data Bridge Market Research analyses that the influenza drug market which was USD 960.55 million in 2022, would rocket up to USD 1,084.07 billion by 2030, and is expected to undergo a CAGR of 2.2% during the forecast period. This indicates that the market value. “Multivitamin” dominates the product type segment of the influenza drug market due to increasing awareness about the Influenza drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Influenza Drug Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Type (Influenza A viruses, Influenza B viruses, Influenza C virus, Influenza D viruses), Mechanism of Action Type (Cap-Dependent Endonuclease Inhibitor, Neuraminidase Inhibitor, Matrix-2 (M2) Protein Inhibitor, Viral Uncoating Inhibitors, Immuno modulators, Non steroidal Anti-Inflammatory Drug, Alpha-adrenergic Receptors Agonist and N-Methyl-D-aspartate Receptor Inhibitor), Vaccine Type (Quadrivalent, Trivalent, Anflu and Other), Treatment Type (Medication, Chemoprophylaxis and Others), Route of Administration (Oral, Intradermal, Intramuscular, Intranasal, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

Mylan N.V. (U.S.), GlaxoSmithKline plc. (U.K.), Pfizer Inc. (U.S.), Abbott (U.S.), Eli Lilly And Company (U.S.), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), AstraZeneca (U.K.), DAIICHI SANKYO COMPANY, LIMITED. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), among others

Market Opportunities

  • Rising demand for minimally invasive treatments
  • Development of new formulations and delivery methods
  • Rising personalized medicine approaches

Market Definition

Influenza is a common viral infection that can turn out to be deadly if not treated properly and well in time. It is a contagious respiratory illness that has an adverse effect on the nose, throat and lungs. Caused by influenza viruses, the best treatment for the same is to get a vaccine every year. The most common symptoms of influenza are runny nose, fatigue, muscle pain, headache, fever and congestion. The influenza drug market refers to the segment of the pharmaceutical industry that focuses on the research, development, manufacturing, and sales of drugs used for the prevention, treatment, and management of influenza, commonly known as the flu. Influenza is a highly contagious respiratory illness caused by influenza viruses, and it affects millions of people worldwide each year.

Influenza Drug Market Dynamics

Drivers

  • High Prevalence and Impact of Influenza

Influenza is a widespread respiratory illness that affects millions of people worldwide each year. The seasonal nature of influenza and the potential for severe outbreaks, such as the H1N1 pandemic in 2009, highlight the need for effective drugs to prevent and treat the virus. Hence, high prevalence and impact of influenza is acting as driver for the growth of market

  • Increasing Awareness and Concern for Public Health

Governments and healthcare organizations globally recognize the importance of preventing and controlling influenza outbreaks. Public health initiatives, vaccination campaigns, and awareness programs drive the demand for influenza drugs, both for treatment and prevention

  • Growing Investment in Research and Development  

Both pharmaceutical companies and research institutions are investing significantly in the research and development of influenza drug. This investment is driven by the potential of influenza drugs to address unmet medical needs, resulting in a steady flow of new products and therapies entering the market

  • Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities

Opportunities

  • Development of Next-Generation Antiviral Drugs

There is a constant need for more effective and safer antiviral drugs to combat influenza, especially considering the potential for the emergence of new, drug-resistant strains. Pharmaceutical companies can focus on research and development to create innovative antiviral drugs that offer improved efficacy, reduced side effects, and a broader spectrum of activity against various influenza strains

  • Expansion of Vaccine Production and Distribution

Influenza vaccines are a critical tool in preventing seasonal flu outbreaks. Market opportunities exist for companies involved in vaccine production and distribution to expand their capabilities and reach more populations, including those in underserved regions. In addition, developing vaccines that provide longer-lasting immunity or broader protection against multiple influenza strains could be a lucrative opportunity

Restraints/Challenges

  • Seasonal Demand and Short Product Lifecycle

Influenza drugs typically have a seasonal demand pattern, with peak demand occurring during flu seasons. This can result in revenue fluctuations and challenges for manufacturers in terms of production planning and inventory management. Furthermore, the short product lifecycle of some drugs due to the constant evolution of influenza viruses can limit the long-term profitability of certain products

  • Vaccine Hesitancy and Compliance

Vaccine hesitancy and low compliance rates in some populations can hinder the growth of the influenza vaccine market. Factors such as misinformation, skepticism about vaccine safety, and concerns about vaccine effectiveness can contribute to lower vaccination rates, reducing the overall market potential for preventive measures

  • Viral Variability and Seasonal Shifts

Influenza viruses continually evolve and mutate, leading to changes in viral strains each flu season. This variability challenges drug developers and vaccine manufacturers to keep up with the rapid changes and develop effective treatments and vaccines that cover the prevalent strains. Anticipating which strains will be dominant in a given season can be challenging

  • Vaccine Manufacturing and Supply Chain Issues

Ensuring a stable and sufficient supply of influenza vaccines can be challenging. Vaccine manufacturing involves complex processes, and unexpected disruptions, such as production issues or supply chain interruptions, can lead to vaccine shortages. Maintaining a consistent vaccine supply to meet global demand is a significant challenge, especially during pandemics

This influenza drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the influenza drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

  • In November 2020, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis

Global Influenza Drug Market Scope

The influenza drug market is segmented on the basis of type, mechanism of action type, vaccine type, treatment type, route of administration, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Influenza A viruses
  • Influenza B viruses
  • Influenza C virus
  • Influenza D viruses

 Mechanism of Action Type

  • Cap-Dependent Endonuclease Inhibitor
  • Neuraminidase Inhibitor
  • Oseltamivir
  • Zanamivir
  • Peramivir
  • Laninamivir octanoate
  • Matrix-2 (M2) Protein Inhibitor
  • Viral Uncoating Inhibitors
  • Immuno modulators
  • No steroidal Anti-Inflammatory Drug
  • Aspirin
  • Ibuprofen
  • Celecoxib
  • Alpha-adrenergic Receptors Agonist
  • N-Methyl-D-aspartate Receptor Inhibitor

Vaccine Type

  • Quadrivalent
  • Trivalent
  • Anflu
  • Other

Treatment Type

  • Medication
  • Chemoprophylaxis
  • Others

Route of Administration

  • Oral
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravenous
  • Others

End-User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Global Influenza Drug Market Regional Analysis/Insights

The influenza drug market is analysed and market size insights and trends are provided by type, mechanism of action type, vaccine type, treatment type, route of administration, and end-user as referenced above.

The countries covered in the influenza drug market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa

North America is dominating the global Influenza drug market due to the increasing prevalence of influenza in that region.

Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 due to increasing rising awareness and influenza.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Influenza Drug Market Share Analysis

The influenza drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to influenza drug market.

Some of the major players operating in the influenza drug market are:

  • Mylan N.V. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • Pfizer Inc. (U.S.)
  • Abbott (U.S.)
  • Eli Lilly And Company (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Takeda Pharmaceutical Company Limited. (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • AstraZeneca (U.K.)
  • DAIICHI SANKYO COMPANY, LIMITED. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sandoz International GmbH (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The influenza drug market size will be worth USD 1,084.07 billion by 2030
The growth rate of the influenza drug market is 2.2% in the forecast by 2030.
High prevalence and impact of influenza, increasing awareness and concern for public health & growing investment in research and development are the growth drivers of the influenza drug market.
Type, mechanism of action type, vaccine type, treatment type, route of administration, and end-user are the factors on which the influenza drug market research is based.
Major companies in the influenza drug market are Mylan N.V. (U.S.), GlaxoSmithKline plc. (U.K.), Pfizer Inc. (U.S.), Abbott (U.S.), Eli Lilly And Company (U.S.), Bristol-Myers Squibb Company (U.S.), Takeda Pharmaceutical Company Limited. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (U.S.), Sanofi (France), Novartis AG (Switzerland), AstraZeneca (U.K.), DAIICHI SANKYO COMPANY, LIMITED. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), among others
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials